The vast majority of cancer-associated p53 mutants are full-length proteins, typically with only a single amino acid substitution, which tend to accumulate in the tumour cells and reach steady-state levels that greatly exceed those of wild-type p53 (wt p53) in noncancerous cells8. This evidence concerns the gene TP53 and cancer.